Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. It is principally associated with liver cirrhosis and chronic liver disease. The major risk factors for the development of HCC include viral infections (HBV, HCV), alcoholic liver disease (ALD,) and non-alcoholic fatty liver...
Gespeichert in:
| Veröffentlicht in: | Journal of personalized medicine 2022-03, Vol.12 (3), p.436 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 436 |
| container_title | Journal of personalized medicine |
| container_volume | 12 |
| creator | Kotsifa, Evgenia Vergadis, Chrysovalantis Vailas, Michael Machairas, Nikolaos Kykalos, Stylianos Damaskos, Christos Garmpis, Nikolaos Lianos, Georgios D Schizas, Dimitrios |
| description | Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. It is principally associated with liver cirrhosis and chronic liver disease. The major risk factors for the development of HCC include viral infections (HBV, HCV), alcoholic liver disease (ALD,) and non-alcoholic fatty liver disease (NAFLD). The optimal treatment choice is dictated by multiple variables such as tumor burden, liver function, and patient's health status. Surgical resection, transplantation, ablation, transarterial chemoembolization (TACE), and systemic therapy are potentially useful treatment strategies. TACE is considered the first-line treatment for patients with intermediate stage HCC. The purpose of this review was to assess the indications, the optimal treatment schedule, the technical factors associated with TACE, and the overall application of TACE as a personalized treatment for HCC. |
| doi_str_mv | 10.3390/jpm12030436 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8955120</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2644005855</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-4593325d8099d8a56d2fde4078f3400ebb3420ca53dee56de1400a319b54f4913</originalsourceid><addsrcrecordid>eNpdkd9LwzAQx4Mobsw9-S4FXwRXTfOja31QpKgTJr5MfAxpe3UZbTOTVpl_vambY3oPuSP3uctdvggdB_iC0hhfLpZVQDDFjIZ7qE_wmPuMkXB_J-6hobUL7CzihIT4EPUopz8lffQ0M7K20jRglCy9ZA6VhirVpfqSjdK1V2jjTWApG51BWbalNF4iTaZqXckr73W-GrkD6pE30Z83R-igkKWF4cYP0Mv93SyZ-NPnh8fkdupnDMeNz3hMKeF5hOM4jyQPc1LkwPA4KijDGNKUMoIzyWkO4LIQuFtJgzjlrGBxQAfoet132aYV5BnUjZGlWBpVSbMSWirxN1OruXjTHyKKOe_-a4DONg2Mfm_BNqJStltQ1qBbK0jI3JM84tyhp__QhW5N7dbrKMI4JoQ46nxNZUZba6DYDhNg0SkldpRy9Mnu_Fv2Vxf6DUVJjY4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2642450222</pqid></control><display><type>article</type><title>Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kotsifa, Evgenia ; Vergadis, Chrysovalantis ; Vailas, Michael ; Machairas, Nikolaos ; Kykalos, Stylianos ; Damaskos, Christos ; Garmpis, Nikolaos ; Lianos, Georgios D ; Schizas, Dimitrios</creator><creatorcontrib>Kotsifa, Evgenia ; Vergadis, Chrysovalantis ; Vailas, Michael ; Machairas, Nikolaos ; Kykalos, Stylianos ; Damaskos, Christos ; Garmpis, Nikolaos ; Lianos, Georgios D ; Schizas, Dimitrios</creatorcontrib><description>Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. It is principally associated with liver cirrhosis and chronic liver disease. The major risk factors for the development of HCC include viral infections (HBV, HCV), alcoholic liver disease (ALD,) and non-alcoholic fatty liver disease (NAFLD). The optimal treatment choice is dictated by multiple variables such as tumor burden, liver function, and patient's health status. Surgical resection, transplantation, ablation, transarterial chemoembolization (TACE), and systemic therapy are potentially useful treatment strategies. TACE is considered the first-line treatment for patients with intermediate stage HCC. The purpose of this review was to assess the indications, the optimal treatment schedule, the technical factors associated with TACE, and the overall application of TACE as a personalized treatment for HCC.</description><identifier>ISSN: 2075-4426</identifier><identifier>EISSN: 2075-4426</identifier><identifier>DOI: 10.3390/jpm12030436</identifier><identifier>PMID: 35330436</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Ablation ; Chemotherapy ; Cirrhosis ; Contraindications ; Cytotoxicity ; Developing countries ; Embolization ; Fatty liver ; Hepatitis B ; Hepatocellular carcinoma ; Hypertension ; Immunization ; LDCs ; Liver cancer ; Liver cirrhosis ; Liver diseases ; Malignancy ; Medical prognosis ; Patients ; Precision medicine ; Radiation ; Response rates ; Review ; Risk factors ; Thrombosis ; Transplantation ; Tumors ; Veins & arteries</subject><ispartof>Journal of personalized medicine, 2022-03, Vol.12 (3), p.436</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-4593325d8099d8a56d2fde4078f3400ebb3420ca53dee56de1400a319b54f4913</citedby><cites>FETCH-LOGICAL-c409t-4593325d8099d8a56d2fde4078f3400ebb3420ca53dee56de1400a319b54f4913</cites><orcidid>0000-0001-9980-0056 ; 0000-0002-5454-2564 ; 0000-0002-0788-7009 ; 0000-0003-3239-3905 ; 0000-0002-6106-8178 ; 0000-0001-5443-1058 ; 0000-0002-7357-6532 ; 0000-0002-7046-0112 ; 0000-0002-8687-685X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955120/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955120/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35330436$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kotsifa, Evgenia</creatorcontrib><creatorcontrib>Vergadis, Chrysovalantis</creatorcontrib><creatorcontrib>Vailas, Michael</creatorcontrib><creatorcontrib>Machairas, Nikolaos</creatorcontrib><creatorcontrib>Kykalos, Stylianos</creatorcontrib><creatorcontrib>Damaskos, Christos</creatorcontrib><creatorcontrib>Garmpis, Nikolaos</creatorcontrib><creatorcontrib>Lianos, Georgios D</creatorcontrib><creatorcontrib>Schizas, Dimitrios</creatorcontrib><title>Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?</title><title>Journal of personalized medicine</title><addtitle>J Pers Med</addtitle><description>Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. It is principally associated with liver cirrhosis and chronic liver disease. The major risk factors for the development of HCC include viral infections (HBV, HCV), alcoholic liver disease (ALD,) and non-alcoholic fatty liver disease (NAFLD). The optimal treatment choice is dictated by multiple variables such as tumor burden, liver function, and patient's health status. Surgical resection, transplantation, ablation, transarterial chemoembolization (TACE), and systemic therapy are potentially useful treatment strategies. TACE is considered the first-line treatment for patients with intermediate stage HCC. The purpose of this review was to assess the indications, the optimal treatment schedule, the technical factors associated with TACE, and the overall application of TACE as a personalized treatment for HCC.</description><subject>Ablation</subject><subject>Chemotherapy</subject><subject>Cirrhosis</subject><subject>Contraindications</subject><subject>Cytotoxicity</subject><subject>Developing countries</subject><subject>Embolization</subject><subject>Fatty liver</subject><subject>Hepatitis B</subject><subject>Hepatocellular carcinoma</subject><subject>Hypertension</subject><subject>Immunization</subject><subject>LDCs</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Malignancy</subject><subject>Medical prognosis</subject><subject>Patients</subject><subject>Precision medicine</subject><subject>Radiation</subject><subject>Response rates</subject><subject>Review</subject><subject>Risk factors</subject><subject>Thrombosis</subject><subject>Transplantation</subject><subject>Tumors</subject><subject>Veins & arteries</subject><issn>2075-4426</issn><issn>2075-4426</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkd9LwzAQx4Mobsw9-S4FXwRXTfOja31QpKgTJr5MfAxpe3UZbTOTVpl_vambY3oPuSP3uctdvggdB_iC0hhfLpZVQDDFjIZ7qE_wmPuMkXB_J-6hobUL7CzihIT4EPUopz8lffQ0M7K20jRglCy9ZA6VhirVpfqSjdK1V2jjTWApG51BWbalNF4iTaZqXckr73W-GrkD6pE30Z83R-igkKWF4cYP0Mv93SyZ-NPnh8fkdupnDMeNz3hMKeF5hOM4jyQPc1LkwPA4KijDGNKUMoIzyWkO4LIQuFtJgzjlrGBxQAfoet132aYV5BnUjZGlWBpVSbMSWirxN1OruXjTHyKKOe_-a4DONg2Mfm_BNqJStltQ1qBbK0jI3JM84tyhp__QhW5N7dbrKMI4JoQ46nxNZUZba6DYDhNg0SkldpRy9Mnu_Fv2Vxf6DUVJjY4</recordid><startdate>20220310</startdate><enddate>20220310</enddate><creator>Kotsifa, Evgenia</creator><creator>Vergadis, Chrysovalantis</creator><creator>Vailas, Michael</creator><creator>Machairas, Nikolaos</creator><creator>Kykalos, Stylianos</creator><creator>Damaskos, Christos</creator><creator>Garmpis, Nikolaos</creator><creator>Lianos, Georgios D</creator><creator>Schizas, Dimitrios</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9980-0056</orcidid><orcidid>https://orcid.org/0000-0002-5454-2564</orcidid><orcidid>https://orcid.org/0000-0002-0788-7009</orcidid><orcidid>https://orcid.org/0000-0003-3239-3905</orcidid><orcidid>https://orcid.org/0000-0002-6106-8178</orcidid><orcidid>https://orcid.org/0000-0001-5443-1058</orcidid><orcidid>https://orcid.org/0000-0002-7357-6532</orcidid><orcidid>https://orcid.org/0000-0002-7046-0112</orcidid><orcidid>https://orcid.org/0000-0002-8687-685X</orcidid></search><sort><creationdate>20220310</creationdate><title>Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?</title><author>Kotsifa, Evgenia ; Vergadis, Chrysovalantis ; Vailas, Michael ; Machairas, Nikolaos ; Kykalos, Stylianos ; Damaskos, Christos ; Garmpis, Nikolaos ; Lianos, Georgios D ; Schizas, Dimitrios</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-4593325d8099d8a56d2fde4078f3400ebb3420ca53dee56de1400a319b54f4913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Ablation</topic><topic>Chemotherapy</topic><topic>Cirrhosis</topic><topic>Contraindications</topic><topic>Cytotoxicity</topic><topic>Developing countries</topic><topic>Embolization</topic><topic>Fatty liver</topic><topic>Hepatitis B</topic><topic>Hepatocellular carcinoma</topic><topic>Hypertension</topic><topic>Immunization</topic><topic>LDCs</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Malignancy</topic><topic>Medical prognosis</topic><topic>Patients</topic><topic>Precision medicine</topic><topic>Radiation</topic><topic>Response rates</topic><topic>Review</topic><topic>Risk factors</topic><topic>Thrombosis</topic><topic>Transplantation</topic><topic>Tumors</topic><topic>Veins & arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kotsifa, Evgenia</creatorcontrib><creatorcontrib>Vergadis, Chrysovalantis</creatorcontrib><creatorcontrib>Vailas, Michael</creatorcontrib><creatorcontrib>Machairas, Nikolaos</creatorcontrib><creatorcontrib>Kykalos, Stylianos</creatorcontrib><creatorcontrib>Damaskos, Christos</creatorcontrib><creatorcontrib>Garmpis, Nikolaos</creatorcontrib><creatorcontrib>Lianos, Georgios D</creatorcontrib><creatorcontrib>Schizas, Dimitrios</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of personalized medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kotsifa, Evgenia</au><au>Vergadis, Chrysovalantis</au><au>Vailas, Michael</au><au>Machairas, Nikolaos</au><au>Kykalos, Stylianos</au><au>Damaskos, Christos</au><au>Garmpis, Nikolaos</au><au>Lianos, Georgios D</au><au>Schizas, Dimitrios</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?</atitle><jtitle>Journal of personalized medicine</jtitle><addtitle>J Pers Med</addtitle><date>2022-03-10</date><risdate>2022</risdate><volume>12</volume><issue>3</issue><spage>436</spage><pages>436-</pages><issn>2075-4426</issn><eissn>2075-4426</eissn><abstract>Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. It is principally associated with liver cirrhosis and chronic liver disease. The major risk factors for the development of HCC include viral infections (HBV, HCV), alcoholic liver disease (ALD,) and non-alcoholic fatty liver disease (NAFLD). The optimal treatment choice is dictated by multiple variables such as tumor burden, liver function, and patient's health status. Surgical resection, transplantation, ablation, transarterial chemoembolization (TACE), and systemic therapy are potentially useful treatment strategies. TACE is considered the first-line treatment for patients with intermediate stage HCC. The purpose of this review was to assess the indications, the optimal treatment schedule, the technical factors associated with TACE, and the overall application of TACE as a personalized treatment for HCC.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35330436</pmid><doi>10.3390/jpm12030436</doi><orcidid>https://orcid.org/0000-0001-9980-0056</orcidid><orcidid>https://orcid.org/0000-0002-5454-2564</orcidid><orcidid>https://orcid.org/0000-0002-0788-7009</orcidid><orcidid>https://orcid.org/0000-0003-3239-3905</orcidid><orcidid>https://orcid.org/0000-0002-6106-8178</orcidid><orcidid>https://orcid.org/0000-0001-5443-1058</orcidid><orcidid>https://orcid.org/0000-0002-7357-6532</orcidid><orcidid>https://orcid.org/0000-0002-7046-0112</orcidid><orcidid>https://orcid.org/0000-0002-8687-685X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2075-4426 |
| ispartof | Journal of personalized medicine, 2022-03, Vol.12 (3), p.436 |
| issn | 2075-4426 2075-4426 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8955120 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Ablation Chemotherapy Cirrhosis Contraindications Cytotoxicity Developing countries Embolization Fatty liver Hepatitis B Hepatocellular carcinoma Hypertension Immunization LDCs Liver cancer Liver cirrhosis Liver diseases Malignancy Medical prognosis Patients Precision medicine Radiation Response rates Review Risk factors Thrombosis Transplantation Tumors Veins & arteries |
| title | Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T09%3A21%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transarterial%20Chemoembolization%20for%20Hepatocellular%20Carcinoma:%20Why,%20When,%20How?&rft.jtitle=Journal%20of%20personalized%20medicine&rft.au=Kotsifa,%20Evgenia&rft.date=2022-03-10&rft.volume=12&rft.issue=3&rft.spage=436&rft.pages=436-&rft.issn=2075-4426&rft.eissn=2075-4426&rft_id=info:doi/10.3390/jpm12030436&rft_dat=%3Cproquest_pubme%3E2644005855%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2642450222&rft_id=info:pmid/35330436&rfr_iscdi=true |